Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax
Authors:
Open Access
- 1 May 2010
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 201 (9) , 1353-1360
Abstract
(See the article by Wilck et al, on pages 1361–1370.)Background. Despite the success of smallpox vaccination, the immunological correlates of protectKeywords
This publication has 29 references indexed in Scilit:
- Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4Journal of Virology, 2004
- Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination11The views expressed in this study are those of the authors and do not reflect the official policy or position of the U.S. government.JACC, 2004
- Modified Vaccinia Ankara: Potential as an Alternative Smallpox VaccineClinical Infectious Diseases, 2004
- Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal MonkeypoxJournal of Virology, 2004
- Smallpox vaccination and myopericarditis: a clinical reviewJACC, 2004
- Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxNature, 2004
- Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine virusesProceedings of the National Academy of Sciences, 2003
- Smallpox Vaccination: A Review, Part I. Background, Vaccination Technique, Normal Vaccination and Revaccination, and Expected Normal ReactionsClinical Infectious Diseases, 2003
- MINIMUM PROTECTIVE LEVEL OF ANTIBODIES IN SMALLPOX1975
- A Prospective Study of Serum Antibody and Protection Against SmallpoxThe American Journal of Tropical Medicine and Hygiene, 1972